Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Shionogi_&_Co.
|
| https://www.w3.org/2000/01/rdf-schema#label |
SPT-615
|
| gptkbp:mechanismOfAction |
protease inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:SARS-CoV-2_main_protease
|
| gptkbp:usedFor |
treatment of COVID-19
|
| gptkbp:bfsParent |
gptkb:SPT_615
|
| gptkbp:bfsLayer |
8
|